Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic ratsHEPATOLOGY COMMUNICATIONSIF4.62022-05-206OAAI
Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty LiverHEPATOLOGY COMMUNICATIONSIF4.62021-12-237OAAI
Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic OptionsJOURNAL OF CLINICAL MEDICINEIF2.92021-02-1128OA
Cirrhotic portal hypertension: From pathophysiology to novel therapeuticsWORLD JOURNAL OF GASTROENTEROLOGYIF5.42020-10-2861OAAI
Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout MiceHEPATOLOGY COMMUNICATIONSIF4.62019-10-1034OAAI
Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive RatsFRONTIERS IN PHYSIOLOGYIF3.42019-09-208OAAI
Mas-related G-protein coupled receptor type D (MrgD) antagonism produces splanchnic vasculature-specific effects, leading to a large reduction in portal pressure in cirrhotic animalsJOURNAL OF HEPATOLOGYIF332018-04-010PREAI